[Treatment of Guillain-barre syndrome: immunoglobulins or plasmapheresis?].
The aim of this study was to compare the efficacy of IgIV versus plasmapheresis in the treatment of Guillain-Barré syndrome. Twenty-four Guillain-Barré patients were treated either with IgIV (n = 17), or plasmapheresis (n = 7). Evolution during the first year after onset were assessed using the motor functional scale of Hughes and nerve conduction studies. IgIV treated patients had better functional recovery than the plasmapheresis group (p < 0.05) and shorter hospital stays (p < 0.05). These differences were significant from day 30 after treatment. Complications occurred in 14 patients: 9 (58%) in the IgIV group, and 5 (71%) in the patients treated with plasmapheresis. IgIV treated patients had better functional recovery scores and shorter hospital stays. There were no differences in the complication rates. Therefore we believe that IgIV is the treatment of choice for Guillain-Barré syndrome in our clinical setting.
Martínez Yélamos
A
A
Servicio de Neurología, Ciudad Sanitaria y Universitaria de Bellvitge, L'Hospitalet de Llobregat, Barcelona.
Huerta Villanueva
M
M
Olivé Plana
M
M
Montero Homs
J
J
Serra Catafau
J
J
Martínez-Matos
J A
JA
D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010956:Plasmapheresis / Q000379:methods*; D011129:Polyradiculoneuropathy / Q000628:therapy*
D016756:Immunoglobulins, Intravenous
Tratamiento del síndrome de Guillain-Barré: inmunoglobulinas o plasmaféresis?